Analysis of Faricimab Treatment Outcomes for Age-Related Macular Degeneration

Exploring Patient and Treatment Factors Affecting Real-World Long-Term Visual Outcomes of Faricimab Proactive Therapy in Neovascular Age-Related Macular Degeneration - Outcome of faricimab proactive treatment for neovascular age-related macular degeneration

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057804

Enrollment

Registered

2025-05-08

Start date

2022-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neovascular age-related macular degeneration (nAMD)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients over 50 years of age with neovascular age-related macular degeneration who have been followed for 2 years.

Exclusion criteria

Exclusion criteria: Patients who have received any previous treatment for neovascular age-related macular degeneration, patients with other retinal diseases, and patients with high myopia

Design outcomes

Primary

Measure	Time frame
Amount of change in visual acuity after 2 years of treatment	—

Secondary

Measure	Time frame
1. Retinal thickness and exudative changes during the course of treatment 2. Factors associated with the development of fibrotic scarring during treatment 3. Treatment outcome in subtypes such as PCV and pachychoroid 4. Visual course, number of treatments, and dosing interval 5. Search for prognostic factors (retinal imaging biomarkers such as OCT and OCTA)	—

Countries

Japan

Contacts

Public ContactMasayuki Hata

Kyoto University Hospital Kyoto University Hospital Clinical Research Consultation Desk

ctsodan@kuhp.kyoto-u.ac.jp075-751-4748

Outcome results